Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia & Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial

<p>SAN DIEGO, Dec. 08, 2023 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and The Leukemia & Lymphoma Society (LLS), the largest private funder of blood cancer research, today announced a clinical collaboration to evaluate Kura’s menin inhibitor, […]</p>
<p>The post <a href="https://forextv.com/top-news/kura-oncologys-menin-inhibitor-ziftomenib-selected-for-the-leukemia-lymphoma-societys-pediatric-acute-leukemia-pedal-master-clinical-trial/">Kura Oncology’s Menin Inhibitor Ziftomenib Selected for The Leukemia &amp; Lymphoma Society’s Pediatric Acute Leukemia (PedAL) Master Clinical Trial</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>